Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes

• Published in: Diabetes care Vol. 40; no. 2; pp. 284 - 286
• Main Authors: Tkáč, Ivan, Raz, Itamar
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.02.2017
• Subjects: Acute Disease; Adamantane - administration & dosage; Adamantane - adverse effects; Adamantane - analogs & derivatives; Cardiovascular system; Clinical trials; Diabetes Mellitus, Type 2 - drug therapy; Dipeptides - administration & dosage; Dipeptides - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Humans; Incidence; Medical treatment; Pancreatitis - chemically induced; Pancreatitis - epidemiology; Piperidines - administration & dosage; Piperidines - adverse effects; Randomized Controlled Trials as Topic; Risk assessment; Sitagliptin Phosphate - administration & dosage; Sitagliptin Phosphate - adverse effects; Uracil - administration & dosage; Uracil - adverse effects; Uracil - analogs & derivatives

Data on the possible relationship of gliptin treatment with the incidence of acute pancreatitis have been controversial. The aim of the current study was to combine data on the incidence of acute pancreatitis from three large randomized controlled trials. Three trials designed to test cardiovascular...